4 stories mentioning QDEL
Every FINWIRES story that references QDEL, newest first.
QuidelOrtho (QDEL) has an average rating of hold and mean price target of $18.10, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.7%.The iShares Biotechnology ETF (IBB) dropped 1.3%.In corporate news, Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported Q1 results above market estimates. Its shares fell past 5%.Gilead Sciences (GILD) could beat Q1 consensus estimates, but weaker-than-expected persistence rates for Yeztugo point to a potential risk to long-term peak sales for the HIV pre-exposure prophylaxis drug, RBC Capital Markets said in a note. Gilead shares were down 0.8%.QuidelOrtho (QDEL) shares tumbled 28%. The company said late Wednesday it expects preliminary unaudited revenue of $615 million to $620 million for Q1. Analysts polled by FactSet expect $677.8 million.Hims & Hers Health (HIMS) shares jumped past 12% after a senior US health official signaled plans to ease restrictions on certain peptides.
Health care stocks declined Thursday afternoon, with the NYSE Health Care Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 1%.The iShares Biotechnology ETF (IBB) dropped 1.2%.In corporate news, Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported Q1 results above market estimates. Its shares fell past 6%.QuidelOrtho (QDEL) shares tumbled 31%. The company said late Wednesday it expects preliminary unaudited revenue of $615 million to $620 million for Q1. Analysts polled by FactSet expect $677.8 million.Hims & Hers Health (HIMS) shares rose past 7% after a senior US health official signaled plans to ease restrictions on certain peptides.Organon (OGN) is a potential acquisition target by India's Sun Pharmaceutical Industries, Germany's Grunenthal, and private equity firms, Bloomberg reported. Organon shares added 0.7%.
QuidelOrtho (QDEL) shares slumped 32% amid heavy trading after the company set out late Wednesday expectations for preliminary unaudited revenue below market expectations for Q1.Intraday trading volume surged to over 8.5 million shares from a daily average of about 1.6 million.MIND Technology (MIND) reported late Wednesday a fiscal Q4 loss and a year-over-year decline in revenue.Shares slumped 27% as intraday trading volume climbed to more than 895,000 from a daily average of about 153,000.Allbirds (BIRD) fell by 28% after midday, swinging from a 582% surge at Wednesday's close. The company said Wednesday it has executed a definitive agreement with an institutional investor for a $50 million convertible financing facility that will enable a pivot in its business to artificial intelligence compute infrastructure.More than 25.8 million shares of the company traded intraday compared with a daily average of about 4.9 million.Price: $11.91, Change: $-5.58, Percent Change: -31.90%